查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701396

美國子宮肌瘤治療設備市場規模、佔有率、趨勢分析報告：按技術、治療模式、細分市場預測，2025-2030 年

U.S. Uterine Fibroids Treatment Devices Market Size, Share & Trends Analysis Report By Technology (Surgical Techniques, Laparoscopic Techniques), By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國子宮肌瘤治療設備市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，美國子宮肌瘤治療設備市場規模預計到2030年將達到47.1億美元，2025年至2030年期間的複合年成長率為9.3%。

由於人們對子宮肌瘤治療方案的認知不斷提高、微創手術的進步以及對子宮切除術替代方案的保留子宮手術的需求不斷增加，美國子宮肌瘤治療設備行業正在經歷顯著成長。此外，育齡婦女子宮肌瘤盛行率的增加和創新治療設備的普及是推動市場擴張的主要因素。

子宮肌瘤治療設備的創新不斷改變患者的照護。最近的 FDA核准和產品發佈為更有效、更少侵入性的治療方案鋪平了道路。 2024 年 9 月，專門為症狀性子宮肌瘤提供微創解決方案的醫療設備公司 Gynesonics Inc. 宣佈為其 Sonata 系統發布新的 SMART OS 2.4 軟體技術。這種創新治療方法將第一個也是唯一一個子宮內超音波系統與專有的先進射頻消融設備相結合，為治療有症狀的子宮肌瘤提供了一種無切口、保留子宮、經子宮頸的選擇。這些進步凸顯了該行業致力於改善患者治療效果同時降低手術風險的承諾。

市場正在轉向非手術、保留子宮的治療方法。子宮切除術等傳統外科手術正在被侵入性較小的方法所取代，這些方法可以縮短恢復時間、減少併發症並提高患者的生活品質。子子宮鏡肌瘤摘除、腹腔鏡肌瘤摘除和非侵入性超音波治療越來越受到患者和醫療保健提供者的歡迎。

由於技術不斷進步、微創手術的保險覆蓋範圍不斷擴大以及人們對女性生殖健康的興趣日益濃厚，美國子宮肌瘤治療設備行業有望持續成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國子宮肌瘤治療設備市場變數、趨勢與範圍

  • 市場展望
    • 附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國子宮肌瘤治療設備市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國子宮肌瘤治療設備市場：按技術分類的預測和趨勢分析

  • 細分儀表板
  • 美國子宮肌瘤治療設備市場技術波動分析
  • 美國子宮肌瘤治療設備市場規模及趨勢分析（依技術分類，2018-2030）
  • 手術技術
    • 子宮切除術
    • 子宮肌瘤切除術
  • 腹腔鏡手術
    • 腹腔鏡子宮肌瘤切除術
    • 肌溶解症
  • 消融技術
    • 微波消融
    • 熱液燒蝕
    • 冷凍療法
    • 超音波消融
  • 栓塞治療

第5章美國子宮肌瘤治療設備市場：按治療模式的估計和趨勢分析

  • 細分儀表板
  • 美國子宮肌瘤治療器材市場依治療模式波動分析
  • 美國子宮肌瘤治療器械市場規模及趨勢分析（依治療方式，2018-2030年）
  • 侵入性治療
  • 微創治療
  • 非侵入性治療

第6章競爭格局

  • 市場參與企業分類
  • 主要企業簡介
  • Medtronic
  • Stryker
  • Boston Scientific Corporation
  • Insightec.
  • CooperSurgical Inc.
  • Hologic, Inc.
  • CONMED Corporation.
  • Merit Medical Systems.
  • Minerva Surgical, Inc.
Product Code: GVR-4-68040-544-1

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends:

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry's commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women's reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

  • Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
  • Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
  • In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Third Party Perspective
    • 1.3.5. Primary research
    • 1.3.6. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of uterine fibroids
      • 3.2.1.2. Advancements in minimally invasive procedures
      • 3.2.1.3. Increasing awareness and early diagnosis
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of advanced treatment devices
  • 3.3. U.S. Uterine Fibroids Treatment Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Uterine Fibroids Treatment Devices Market Technology Movement Analysis
  • 4.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 4.4. Surgical Techniques
    • 4.4.1. Surgical Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Hysterectomy
      • 4.4.2.1. Hysterectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Myomectomy
      • 4.4.3.1. Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Laparoscopic Techniques
    • 4.5.1. Laparoscopic Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Laparoscopic Myomectomy
      • 4.5.2.1. Laparoscopic Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Myolysis
      • 4.5.3.1. Myolysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Ablation Techniques
    • 4.6.1. Ablation Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Microwave Abalation
      • 4.6.2.1. Microwave Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Hydrothermal Abalation
      • 4.6.3.1. Hydrothermal Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Cyroablation
      • 4.6.4.1. Cyroablation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Ultrasound Abalation
      • 4.6.5.1. Ultrasound Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.5.2. High Intensity Focused Ultrasound (HIFU)
        • 4.6.5.2.1. High Intensity Focused Ultrasound (HIFU) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.5.3. MRI-guided Focused Ultrasound (MRgFUS)
        • 4.6.5.3.1. MRI-guided Focused Ultrasound (MRgFUS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Embolization Techniques
    • 4.7.1. Embolization Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Uterine Fibroids Treatment Devices Market Mode of Treatment Movement Analysis
  • 5.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Mode of Treatment, 2018 to 2030 (USD Million)
  • 5.4. Invasive Treatment
    • 5.4.1. Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Minimally Invasive Treatment
    • 5.5.1. Minimally Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-invasive Treatment
    • 5.6.1. Non-invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
  • 6.2. Key Company Profiles
    • 6.2.1. Medtronic
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
  • 6.3. Stryker
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Service Benchmarking
      • 6.3.1.4. Strategic Initiatives
  • 6.4. Boston Scientific Corporation
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Service Benchmarking
      • 6.4.1.4. Strategic Initiatives
  • 6.5. Insightec.
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Service Benchmarking
      • 6.5.1.4. Strategic Initiatives
  • 6.6. CooperSurgical Inc.
      • 6.6.1.1. Company Overview
      • 6.6.1.2. Financial Performance
      • 6.6.1.3. Service Benchmarking
      • 6.6.1.4. Strategic Initiatives
  • 6.7. Hologic, Inc.
      • 6.7.1.1. Company Overview
      • 6.7.1.2. Financial Performance
      • 6.7.1.3. Service Benchmarking
      • 6.7.1.4. Strategic Initiatives
  • 6.8. CONMED Corporation.
      • 6.8.1.1. Company Overview
      • 6.8.1.2. Financial Performance
      • 6.8.1.3. Service Benchmarking
      • 6.8.1.4. Strategic Initiatives
  • 6.9. Merit Medical Systems.
      • 6.9.1.1. Company Overview
      • 6.9.1.2. Financial Performance
      • 6.9.1.3. Service Benchmarking
      • 6.9.1.4. Strategic Initiatives
  • 6.10. Minerva Surgical, Inc.
      • 6.10.1.1. Company Overview
      • 6.10.1.2. Financial Performance
      • 6.10.1.3. Service Benchmarking
      • 6.10.1.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. U.S. Uterine Fibroids Treatment Devices Market, By Technology, 2018 - 2030 (USD Million)
  • Table 4. U.S. Uterine Fibroids Treatment Devices Market, By Mode of Treatment, 2018 - 2030 (USD Million)
  • Table 5. Participant's Overview
  • Table 6. Financial Performance
  • Table 7. Product Benchmarking
  • Table 8. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 U.S. Uterine Fibroids Treatment Devices Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Market Opportunity Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 U.S. Uterine Fibroids Treatment Devices Market, for Surgical Techniques, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Uterine Fibroids Treatment Devices Market, for Hysterectomy, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Uterine Fibroids Treatment Devices Market, for Myomectomy, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Techniques, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Myomectomy, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Uterine Fibroids Treatment Devices Market, for Myolysis, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Uterine Fibroids Treatment Devices Market, for Ablation Techniques, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Uterine Fibroids Treatment Devices Market, for Microwave Ablation, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Uterine Fibroids Treatment Devices Market, for Hydrothermal Ablation, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Uterine Fibroids Treatment Devices Market, for Cryoablation, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Uterine Fibroids Treatment Devices Market, for Ultrasound Ablation, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Uterine Fibroids Treatment Devices Market, for High Intensity Focused Ultrasound (HIFU), 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Uterine Fibroids Treatment Devices Market, for MRI-guided Focused Ultrasound (MRgFUS), 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Uterine Fibroids Treatment Devices Market, for Embolization Techniques, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Uterine Fibroids Treatment Devices Market, for Invasive Treatment, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Uterine Fibroids Treatment Devices Market, for Minimally Invasive Treatment, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Uterine Fibroids Treatment Devices Market, for Non-invasive Treatment, 2018 - 2030 (USD Million)